Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
about
EGFR/HER-targeted therapeutics in ovarian cancerPaclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentInvestigational agents in development for the treatment of ovarian cancerMetronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyDual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.Bevacizumab and ovarian cancerThe combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancerAngiogenesis-related pathways in the pathogenesis of ovarian cancerQuality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancerClinical response in patients with ovarian cancer treated with metronomic chemotherapy.The changing landscape of therapeutic strategies for recurrent ovarian cancer.Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Oral cyclophosphamide in recurrent ovarian cancer.Metronomics: towards personalized chemotherapy?Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.Radiotherapy-assisted tumor selective metronomic oral chemotherapy.
P2860
Q26863231-ADD39539-CFBB-4B97-ACFD-F54950B01E68Q28073057-C6064CE8-6EA1-4F67-917D-E2A432E9FC79Q33920800-94BF2F7A-CAC7-4B2E-9402-98E79BFCA969Q34993605-8C2B338B-241E-4325-A9FE-C81377F52074Q36359684-9672020A-C6A4-4EB2-86F3-F4C940C3F839Q36527473-624B276B-909D-4C66-AD5A-A96F1CF79301Q36567390-ADC955BA-8E84-48A6-8834-A72D3657E747Q37022524-55262F0D-48E5-4952-9C28-A8E2D107C98BQ37139109-665E8877-F05D-49A9-BE8A-7449A9E7EDD6Q37158433-D383AF93-1AA2-4CD1-B43D-D8DF73AA48EDQ37214382-EF34EA6B-6FAC-4F39-A9BB-72F831B9C33BQ37679904-84DF2DE8-B774-4D9E-B6CC-2C4EFB06A8C0Q38048887-30415548-9A37-4F76-B929-FD19135D5F24Q38071555-363BB678-1378-48B9-957C-5364A0811B14Q38087885-BC9284D8-F266-4263-B9F9-2768C3A11B49Q38110346-3E18BFC8-29A0-44DE-A5BF-AB7F73738FE2Q38218923-6F5B9579-1366-4CBC-AF9D-230A9E63DD02Q38969949-3047DC08-A6BC-48E7-9041-4A610DC8F317Q48247510-659443AD-03A3-41F2-8960-004DD642DF3A
P2860
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Bevacizumab plus low-dose metr ...... with recurrent ovarian cancer.
@en
Bevacizumab plus low-dose metr ...... with recurrent ovarian cancer.
@nl
type
label
Bevacizumab plus low-dose metr ...... with recurrent ovarian cancer.
@en
Bevacizumab plus low-dose metr ...... with recurrent ovarian cancer.
@nl
prefLabel
Bevacizumab plus low-dose metr ...... with recurrent ovarian cancer.
@en
Bevacizumab plus low-dose metr ...... with recurrent ovarian cancer.
@nl
P2093
P50
P356
P1433
P1476
Bevacizumab plus low-dose metr ...... with recurrent ovarian cancer
@en
P2093
Alfonso Sánchez-Muñoz
Cristina Quero-Blanco
César A Rodríguez-Sánchez
César Mendiola
Emilio Alba
Ismael Ghanem
José Miguel Jurado
P304
P356
10.1159/000320602
P577
2010-11-15T00:00:00Z